1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Sorrento, Under Shadow Of Chapter 11, Looks To Move BTK Inhibitor Into Phase III

 
• By Alaric DeArment

The biotech announced promising Phase IIa results for abivertinib in marginal zone lymphoma and is in talks with Chinese regulators about a Phase III trial.

Sorrento announced results from its Phase IIa trial of abivertinib in marginal zone lymphoma • Source: Shutterstock

Sorrento Therapeutics, Inc.’s BTK inhibitor, abivertinib, has potential to fill the vacuum in marginal zone lymphoma (MZL) that AbbVie Inc. and Johnson & Johnson left in April when they withdrew the indication for the BTK/EGFR inhibitor, Imbruvica (imbruvica), in that disease as well as mantle cell lymphoma (MCL) following lackluster Phase III confirmatory trial results. Sorrento could be in an especially strong position if it can continue to show a favorable safety profile.

Sorrento plans to move abivertinib into pivotal Phase III development in China following the announcement of successful Phase IIa results,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Kailera Eyes Global Obesity Market With Hengrui’s Phase III Dual Agonist

 
• By Joseph Haas

With China’s Hengrui reporting successful Phase III data for its dual GLP-1/GIP agonist, licensee Kailera is readying plans to demonstrate better efficacy than current obesity drugs.

Sellas Targets Tambiciclib To Adverse-Risk Frontline AML Patients After Phase II Success

 
• By Alaric DeArment

The biotech announced positive Phase II data for the drug combined with AbbVie/Roche’s Venclexta and BMS’s Vidaza in relapsed/refractory acute myeloid leukemia.

Takeda Prepares Ground For Oveporexton In Narcolepsy

 
• By Alaric DeArment

The drugmaker announced positive results from two Phase III trials for the drug in narcolepsy type 1 that analysts said bode well for the OX2R agonist class as a whole.

Leo Lands Another Big Pharma Pact With Boehringer Spevigo Deal

 
• By Kevin Grogan

Paying €90m upfront for rights to generalized pustular psoriasis drug.

More from R&D

Bayer’s Kerendia Gains Blockbuster Indication For Heart Failure

 
• By Joseph Haas

New US approval in heart failure with preserved or mildly reduced ejection fraction should add to Kerendia’s earning power on top of chronic kidney disease indication.

Takeda Prepares Ground For Oveporexton In Narcolepsy

 
• By Alaric DeArment

The drugmaker announced positive results from two Phase III trials for the drug in narcolepsy type 1 that analysts said bode well for the OX2R agonist class as a whole.

Phase III Success For AstraZeneca’s $5bn Hypertension Hope Baxdrostat

 
• By Andrew McConaghie

Rivals Mineralys could be first to file but AstraZeneca is banking on its cardiovascular market know-how to lead the emerging class.